Supreme Court Extends Pause on Mifepristone Mail and Telehealth Restrictions

Recent court actions have affected how mifepristone, a medication used in abortion, can be prescribed and delivered in the United States. The Supreme Court’s involvement has temporarily maintained access to the drug by mail and telehealth, following a lower court’s attempt to restrict these methods.

On May 1, 2026, a panel from the U.S. Court of Appeals for the Fifth Circuit issued a ruling that halted federal rules permitting teleprescribing and mailing of mifepristone across the country. This decision would have limited how patients could obtain the medication.

Justice Samuel A. Alito Jr. of the U.S. Supreme Court responded on May 4, 2026, by issuing an administrative stay. This action paused the Fifth Circuit’s ruling and temporarily restored nationwide access to mifepristone through telehealth and mail services until at least May 11, 2026.

Justice Alito’s order also set a deadline for Louisiana and other respondents to submit responses to the emergency applications by May 7, 2026. These procedural steps were part of ongoing legal proceedings regarding access to the medication.

What the numbers show

• More than 60 percent of abortions in the U.S. now use medication abortion
• The Supreme Court extended the administrative stay until at least 5 p.m. ET on May 14, 2026
• The FDA’s 2023 rule allowed telehealth prescribing and mail delivery of mifepristone

On May 11, 2026, the Supreme Court extended its administrative stay, continuing to allow mifepristone to be prescribed remotely and sent by mail nationwide until at least May 14, 2026. This extension maintained the status quo while the Court considered further filings and responses.

The Supreme Court’s orders have kept in place the Food and Drug Administration’s 2023 policy, which removed the requirement for in-person dispensing of mifepristone. This policy had been challenged under the Administrative Procedure Act by Louisiana and other parties.

Drug manufacturers Danco Laboratories and GenBioPro submitted emergency appeals to the Supreme Court, seeking to ensure that teleprescribing and mail delivery of mifepristone would remain available during the legal process. Their filings were part of the broader dispute over federal rules for medication abortion access.

Medication abortion, which includes the use of mifepristone, now represents a majority of abortion procedures in the United States. The ongoing legal proceedings will determine how and whether remote prescribing and mail delivery will continue to be permitted under federal law.

* This article is based on publicly available information at the time of writing.